Month: September 2021

Albireo Receives UK MHRA Approval of Bylvay® (odevixibat)

Written by Customer Service on September 8, 2021. Posted in Public Companies.

– Bylvay now approved in U.S., EU and UK as first drug treatment for patients with PFIC – – Only once-daily drug indicated to treat all forms of PFIC – – MHRA decision based on data from the largest Phase 3 PFIC trial to date – BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization for Bylvay (odevixibat) for the treatment of all types of progressive familial intrahepatic cholestasis (PFIC). Bylvay is a potent, non-systemic ileal bile acid transport inhibitor (IBATi), administered as a once-daily capsule or opened and sprinkled onto soft foods and which does not require refrigeration.The MHRA authorization...

Wave Life Sciences to Highlight RNA Editing Capability and AATD and Neurology Programs at 2021 Analyst and Investor Research Webcast on September 28, 2021

Written by Customer Service on September 8, 2021. Posted in Public Companies.

Live webcast scheduled for Tuesday, September 28, 2021 at 10:00 a.m. EDT CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced it will highlight its ADAR-mediated RNA editing capability, including an update on its discovery-stage alpha-1 antitrypsin deficiency (“AATD”) program, as well as its preclinical neurology portfolio and PRISMTM platform advancements at its 2021 Analyst and Investor Research Webcast taking place Tuesday, September 28, 2021 at 10:00 a.m. EDT. The Research Webcast will feature presentations from Wave management and also review data being presented at the TIDES USA: Oligonucleotides & Peptide Therapeutics meeting and the...

Lifequest Subsidiary, Biopipe, Receives Order to Install a 5m3/Day Sewage Wastewater Treatment Plant at a Well-Known Global Wine & Spirits Company’s Bottling Plant

Written by Customer Service on September 8, 2021. Posted in Public Companies.

RIDGEFIELD PARK, NEW JERSEY, Sept. 08, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — LIFEQUEST WORLD CORP (LQWC) subsidiary, Biopipe Global has developed the world’s only highly scalable onsite sludge and chemical free sewage wastewater treatment technology. This plant with capacity of 5m3/day (1,320 gallons per day) is being installed at a recently upgraded facility of a wine and spirits maker with a portfolio of highly desirable global luxury brands. Tanmay Pawale, the Chief Operating Officer of Biopipe, said, “We are pleased to get this order for one of the finest makers of wine and spirits in the world. The plant has already been delivered to the site but some site-specific work remains to be done. We are on target to commission this plant by the end of this month. Once we have successfully demonstrated Biopipe’s treatment...

Patriot Glass Solutions, a Division of C-Bond Systems, Receives Purchase Order from Texas Hospital for $136K, Bringing Total Orders Since June to more than $1.1M

Written by Customer Service on September 8, 2021. Posted in Public Companies.

HOUSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) — C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a nanotechnology solutions company, today announced its Patriot Glass Solutions division has received a purchase order from a Texas hospital for $136,000, bringing its total orders since June 2021 to more than $1.1 million. The custom printed film is being installed on the interior of the hospital to provide privacy from an outdoor courtyard, on two exterior curtain walls, and a skywalk. The Patriot Glass Solutions installation is expected to start mid-September and is being structured as a two-year project. Patriot Glass Solutions protects personal, commercial and government property from looting, rioting, break-ins, and gunfire. Its leading products are C-Bond BRS (ballistic-resistant film system) and C-Bond Secure, as well as other...

ACM Research’s Operating Subsidiary ACM Research (Shanghai) Updates Status of China IPO Process

Written by Customer Service on September 8, 2021. Posted in Public Companies.

FREMONT, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) — ACM Research, Inc. (“ACM”) (NASDAQ: ACMR), a leading supplier of wafer cleaning technologies for advanced semiconductor devices, today provided an update on the status of the proposed initial public offering (“IPO”) and listing of shares of ACM’s operating subsidiary ACM Research (Shanghai), Inc. (“ACM Shanghai”) on the Shanghai Stock Exchange’s Sci-Tech innovAtion boaRd. ACM Shanghai plans to begin preliminary in-person and videoconference meetings with qualified IPO investors in China on September 8, 2021. Further details regarding the timing of the IPO are expected to be posted by the Shanghai Stock Exchange when available. ACM estimates that the IPO and listing process will be completed during the fourth quarter of 2021, but the completion and timing of the IPO are subject...

Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone

Written by Customer Service on September 8, 2021. Posted in Public Companies.

Phase 2 Clinical Trial to Evaluate NBI-921352 for the Treatment of Focal-Onset Seizures in Adults Anticipated in 2021 BURNABY, British Columbia, Sept. 08, 2021 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regulatory milestone with the approval of a clinical trial application (CTA) in Europe, triggering an aggregate payment of $10.0 million to Xenon. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer stated, “This $10 million regulatory milestone from our collaboration with Neurocrine Biosciences marks a significant achievement. We look forward to Neurocrine Biosciences initiating a Phase 2 clinical trial for NBI-921352 for...

Greenbacker Renewable Energy Company Acquires 41-MW Solar Asset in Michigan

Written by Customer Service on September 8, 2021. Posted in Mergers And Acquisitions.

The company acquires its largest project in the state, packaged with an option to add power storage NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) — Greenbacker Renewable Energy Company LLC (“GREC” or “Greenbacker”), a leading owner and operator of sustainable infrastructure and energy efficiency projects, announced today that, through a wholly owned subsidiary, it purchased Heathlands, a 41-MW utility-scale solar project from Prism Power Partners LLC (“Prism”). The to-be-constructed asset is the second project in Prism’s 53-MW 2022 Michigan portfolio, the other being a 12-MW pre-operational solar project which Greenbacker also purchased earlier this year. Heathlands marks Greenbacker’s largest asset in Michigan, as the company continues to expand its footprint in the Great Lakes State. The Heathlands solar project also comes with the...

FEMSA’s Envoy Solutions to acquire Penn Jersey Paper Co., further expanding its footprint in the Mid-Atlantic region of the United States

Written by Customer Service on September 8, 2021. Posted in Mergers And Acquisitions.

MONTERREY, Mexico, Sept. 08, 2021 (GLOBE NEWSWIRE) — Fomento Económico Mexicano, S.A.B. de C.V. (“FEMSA” or the “Company”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) announced today that Envoy Solutions, FEMSA’s specialized distribution subsidiary in the United States, reached an agreement to acquire Penn Jersey Paper Co. (“PJP”), an independent specialized distribution company based in Philadelphia, Pennsylvania. PJP fits well with FEMSA’s distribution footprint along the East Coast, expanding its coverage to include the Philadelphia metro area and New York City. This transaction represents another important step in FEMSA’s strategic path to build a leading national distribution platform in the United States. Revenues of the acquired business for the last twelve months as of June 2021, were over US$ 200 million. The transaction is subject...

Candel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Corporate Highlights

Written by Customer Service on September 8, 2021. Posted in Earnings Releases And Operating Results.

NEEDHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (“the Company”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. “This has been a transformational year for Candel Therapeutics as we continue to execute on our corporate strategy by advancing the development of our lead product candidate from our adenovirus platform, CAN-2409, and our lead product candidate from our HSV platform, CAN-3110, both in areas of significant unmet need,” said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel Therapeutics. “With the completion of our IPO in August and multiple data readouts across our broad pipeline over...

Nightfood Announces Successful Hotel Test, Engages iDEAL Hospitality to Scale High-Margin Hotel Vertical

Written by Customer Service on September 8, 2021. Posted in Earnings Releases And Operating Results.

Management to Host Business Update Call Today at 4:30PM Eastern Time Tarrytown, NY, Sept. 08, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Nightfood Holdings, Inc. (OTCQB: NGTF), the category-pioneering company addressing America’s $50 billion nighttime snacking problem, today announced the completion of a retail pilot test in the lobby shops of a leading international hotel chain. The test, first announced in March 2021, has been confirmed a success. As a result, the testing chain has confirmed the decision to fully launch Nightfood into their lobby shop freezers chain-wide with an expected start date in the fourth quarter of 2021 or the first quarter of 2022. “This is a massive step in establishing and growing the projected billion-dollar night snack category, while further securing our leadership position,” remarked Sean...

Month: September 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals